Non-Destructive Tumor Aggregate Morphology and Viability Quantification at Cellular Resolution, During Development and in Response to Drug.
cellular resolution
morphology
multicellular tumor spheroids
optical coherence tomography
viability
Journal
Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
07
2020
revised:
15
09
2020
accepted:
22
09
2020
pubmed:
3
10
2020
medline:
15
5
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
Three-dimensional (3D) tissue-engineered in vitro models, particularly multicellular spheroids and organoids, have become important tools to explore disease progression and guide the development of novel therapeutic strategies. These avascular constructs are particularly powerful in oncological research due to their ability to mimic several key aspects of in vivo tumors, such as 3D structure and pathophysiologic gradients. Advancement of spheroid models requires characterization of critical features (i.e., size, shape, cellular density, and viability) during model development, and in response to treatment. However, evaluation of these characteristics longitudinally, quantitatively and non-invasively remains a challenge. Herein, Optical Coherence Tomography (OCT) is used as a label-free tool to assess 3D morphologies and cellular densities of tumor spheroids generated via the liquid overlay technique. We utilize this quantitative tool to assess Matrigel's influence on spheroid morphologic development, finding that the absence of Matrigel produces flattened, disk-like aggregates rather than 3D spheroids with physiologically-relevant features. Furthermore, this technology is adapted to quantify cell number within tumor spheroids, and to discern between live and dead cells, to non-destructively provide valuable information on tissue/construct viability, as well as a proof-of-concept for longitudinal drug efficacy studies. Together, these findings demonstrate OCT as a promising noninvasive, quantitative, label-free, longitudinal and cell-based method that can assess development and drug response in 3D cellular aggregates at a mesoscopic scale.
Identifiants
pubmed: 33007490
pii: S1742-7061(20)30565-1
doi: 10.1016/j.actbio.2020.09.042
pmc: PMC7869529
mid: NIHMS1635578
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
322-334Subventions
Organisme : NCI NIH HHS
ID : R01 CA207725
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233188
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cell Div. 2011 Dec 12;6:22
pubmed: 22152157
Oncogene. 2009 Jan 22;28(3):461-8
pubmed: 18978815
Nature. 2003 Aug 21;424(6951):870-2
pubmed: 12931155
Expert Opin Drug Discov. 2012 Sep;7(9):819-30
pubmed: 22788761
Nat Rev Mol Cell Biol. 2014 Oct;15(10):647-64
pubmed: 25237826
Acta Biomater. 2019 Sep 1;95:357-370
pubmed: 30776506
Integr Biol (Camb). 2011 Jan;3(1):31-8
pubmed: 21049126
Neoplasia. 2019 Jun;21(6):615-626
pubmed: 31078067
Biomed Microdevices. 2015 Apr;17(2):33
pubmed: 25681969
Adv Mater. 2019 Sep;31(36):e1901166
pubmed: 31322299
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Biochem Biophys Res Commun. 1982 Aug;107(3):1130-7
pubmed: 7138518
Recent Results Cancer Res. 1984;95:1-23
pubmed: 6396753
Breast Cancer Res Treat. 2006 Mar;96(2):169-76
pubmed: 16331349
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Biotechnol J. 2008 Oct;3(9-10):1172-84
pubmed: 18566957
Lab Chip. 2011 Jan 7;11(1):115-9
pubmed: 21038070
J Anat. 2015 Dec;227(6):746-56
pubmed: 25411113
Cell Tissue Res. 2013 Apr;352(1):161-77
pubmed: 23443300
Sci Rep. 2015 Nov 02;5:15798
pubmed: 26522181
Oncol Rep. 2015 Apr;33(4):1837-43
pubmed: 25634491
Biophys J. 2005 Dec;89(6):3884-94
pubmed: 16199495
ScientificWorldJournal. 2011;11:1829-41
pubmed: 22125441
Skin Res Technol. 2018 May;24(2):265-273
pubmed: 29143429
Comput Methods Programs Biomed. 2016 Oct;135:51-60
pubmed: 27586479
J Biomol Screen. 2004 Jun;9(4):273-85
pubmed: 15191644
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Sci Rep. 2016 Jun 01;6:27017
pubmed: 27248849
Biomaterials. 2007 Dec;28(36):5487-97
pubmed: 17881050
Int J Oncol. 2002 Dec;21(6):1307-15
pubmed: 12429982
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT1-OCT13
pubmed: 27409459
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
Biotechnol Lett. 2007 Feb;29(2):273-8
pubmed: 17160349
Cell Tissue Kinet. 1986 Mar;19(2):205-16
pubmed: 3698078
J Exp Clin Cancer Res. 2018 May 25;37(1):109
pubmed: 29801504
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14843-8
pubmed: 23980147
Oncotarget. 2016 Mar 29;7(13):16948-61
pubmed: 26918944
Biotechnol Bioeng. 2003 Jul 20;83(2):173-80
pubmed: 12768623
Biomed Opt Express. 2016 Oct 07;7(11):4501-4513
pubmed: 27895991
Comput Methods Programs Biomed. 2015 Feb;118(2):95-106
pubmed: 25561413
J Cancer Res Clin Oncol. 1987;113(2):101-22
pubmed: 3549738
Anal Biochem. 2013 Jun 1;437(1):17-9
pubmed: 23435308
J Biomol Screen. 2006 Dec;11(8):922-32
pubmed: 16973921
Biomaterials. 2015;53:609-20
pubmed: 25890757
Cancer Res. 2017 Nov 1;77(21):6011-6020
pubmed: 28904062
Biochem Med (Zagreb). 2015 Jun 05;25(2):141-51
pubmed: 26110027
J Natl Cancer Inst. 1971 Jan;46(1):113-20
pubmed: 5101993
Cancers (Basel). 2019 Nov 01;11(11):
pubmed: 31683901
J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):89-98
pubmed: 27518775
Biomaterials. 2013 Sep;34(28):6615-30
pubmed: 23768903
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238